哮喘中嗜酸性粒细胞气道炎症挥发性特征的发现与验证

IF 19.3 1区 医学 Q1 CRITICAL CARE MEDICINE
Rosa Peltrini, Rebecca L Cordell, Michael Wilde, Shahd Abuhelal, Eleanor Quek, Nazanin Zounemat-Kermani, Wadah Ibrahim, Matthew Richardson, Paul Brinkman, Florence Schleich, Pierre-Hugues Stefanuto, Hnin Aung, Neil Greening, Sven Erik Dahlen, Ratko Djukanovic, Ian M Adcock, Christopher Brightling, Paul Monks, Salman Siddiqui
{"title":"哮喘中嗜酸性粒细胞气道炎症挥发性特征的发现与验证","authors":"Rosa Peltrini, Rebecca L Cordell, Michael Wilde, Shahd Abuhelal, Eleanor Quek, Nazanin Zounemat-Kermani, Wadah Ibrahim, Matthew Richardson, Paul Brinkman, Florence Schleich, Pierre-Hugues Stefanuto, Hnin Aung, Neil Greening, Sven Erik Dahlen, Ratko Djukanovic, Ian M Adcock, Christopher Brightling, Paul Monks, Salman Siddiqui","doi":"10.1164/rccm.202310-1759OC","DOIUrl":null,"url":null,"abstract":"<p><p><b>Rationale:</b> Volatile organic compounds (VOCs) in asthmatic breath may be associated with sputum eosinophilia. We developed a volatile biomarker signature to predict sputum eosinophilia in asthma. <b>Methods:</b> VOCs emitted into the space above sputum samples (headspace) from patients with severe asthma (<i>n</i> = 36) were collected onto sorbent tubes and analyzed using thermal desorption gas chromatography-mass spectrometry (GC-MS). Elastic net regression identified stable VOCs associated with sputum eosinophilia ⩾ 3% and generated a volatile biomarker signature. This VOC signature was validated in breath samples from: <i>1</i>) patients with acute asthma according to blood eosinophilia ⩾0.3 × 10<sup>9</sup>cells/L or sputum eosinophilia of ⩾3% in the UK EMBER (East Midlands Breathomics Pathology Node) consortium (<i>n</i> = 65) and <i>2</i>) U-BIOPRED-IMI (Unbiased Biomarkers in Prediction of Respiratory Disease Outcomes Innovative Medicines Initiative) consortium (<i>n</i> = 42). Breath samples were collected onto sorbent tubes (EMBER) or Tedlar bags (U-BIOPRED) and analyzed by GC-MS (GC × GC-MS for EMBER or GC-MS for U-BIOPRED). <b>Measurements and Main Results:</b> The <i>in vitro</i> headspace identified 19 VOCs associated with sputum eosinophilia, and the derived VOC signature yielded good diagnostic accuracy for sputum eosinophilia ⩾3% in headspace (area under the receiver operating characteristic curve [AUROC] 0.90; 95% confidence interval [CI], 0.80-0.99; <i>P</i> < 0.0001), correlated inversely with sputum eosinophil percentage (<i>r</i><sub>s</sub> = -0.71; <i>P</i> < 0.0001), and outperformed fractional exhaled nitric oxide (AUROC 0.61; 95% CI, 0.35-0.86). Analysis of exhaled breath in replication cohorts yielded a VOC signature AUROC (95% CI) for acute asthma exacerbations of 0.89 (0.76-1.0) (EMBER cohort) with sputum eosinophilia and 0.90 (0.75-1.0) in U-BIOPRED, again outperforming fractional exhaled nitric oxide in U-BIOPRED (0.62 [0.33-0.90]). <b>Conclusions:</b> We have discovered and provided early-stage clinical validation of a volatile biomarker signature associated with eosinophilic airway inflammation. Further work is needed to translate our discovery using point-of-care clinical sensors.</p>","PeriodicalId":7664,"journal":{"name":"American journal of respiratory and critical care medicine","volume":null,"pages":null},"PeriodicalIF":19.3000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11544360/pdf/","citationCount":"0","resultStr":"{\"title\":\"Discovery and Validation of a Volatile Signature of Eosinophilic Airway Inflammation in Asthma.\",\"authors\":\"Rosa Peltrini, Rebecca L Cordell, Michael Wilde, Shahd Abuhelal, Eleanor Quek, Nazanin Zounemat-Kermani, Wadah Ibrahim, Matthew Richardson, Paul Brinkman, Florence Schleich, Pierre-Hugues Stefanuto, Hnin Aung, Neil Greening, Sven Erik Dahlen, Ratko Djukanovic, Ian M Adcock, Christopher Brightling, Paul Monks, Salman Siddiqui\",\"doi\":\"10.1164/rccm.202310-1759OC\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Rationale:</b> Volatile organic compounds (VOCs) in asthmatic breath may be associated with sputum eosinophilia. We developed a volatile biomarker signature to predict sputum eosinophilia in asthma. <b>Methods:</b> VOCs emitted into the space above sputum samples (headspace) from patients with severe asthma (<i>n</i> = 36) were collected onto sorbent tubes and analyzed using thermal desorption gas chromatography-mass spectrometry (GC-MS). Elastic net regression identified stable VOCs associated with sputum eosinophilia ⩾ 3% and generated a volatile biomarker signature. This VOC signature was validated in breath samples from: <i>1</i>) patients with acute asthma according to blood eosinophilia ⩾0.3 × 10<sup>9</sup>cells/L or sputum eosinophilia of ⩾3% in the UK EMBER (East Midlands Breathomics Pathology Node) consortium (<i>n</i> = 65) and <i>2</i>) U-BIOPRED-IMI (Unbiased Biomarkers in Prediction of Respiratory Disease Outcomes Innovative Medicines Initiative) consortium (<i>n</i> = 42). Breath samples were collected onto sorbent tubes (EMBER) or Tedlar bags (U-BIOPRED) and analyzed by GC-MS (GC × GC-MS for EMBER or GC-MS for U-BIOPRED). <b>Measurements and Main Results:</b> The <i>in vitro</i> headspace identified 19 VOCs associated with sputum eosinophilia, and the derived VOC signature yielded good diagnostic accuracy for sputum eosinophilia ⩾3% in headspace (area under the receiver operating characteristic curve [AUROC] 0.90; 95% confidence interval [CI], 0.80-0.99; <i>P</i> < 0.0001), correlated inversely with sputum eosinophil percentage (<i>r</i><sub>s</sub> = -0.71; <i>P</i> < 0.0001), and outperformed fractional exhaled nitric oxide (AUROC 0.61; 95% CI, 0.35-0.86). Analysis of exhaled breath in replication cohorts yielded a VOC signature AUROC (95% CI) for acute asthma exacerbations of 0.89 (0.76-1.0) (EMBER cohort) with sputum eosinophilia and 0.90 (0.75-1.0) in U-BIOPRED, again outperforming fractional exhaled nitric oxide in U-BIOPRED (0.62 [0.33-0.90]). <b>Conclusions:</b> We have discovered and provided early-stage clinical validation of a volatile biomarker signature associated with eosinophilic airway inflammation. Further work is needed to translate our discovery using point-of-care clinical sensors.</p>\",\"PeriodicalId\":7664,\"journal\":{\"name\":\"American journal of respiratory and critical care medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":19.3000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11544360/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of respiratory and critical care medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1164/rccm.202310-1759OC\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CRITICAL CARE MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of respiratory and critical care medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1164/rccm.202310-1759OC","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0

摘要

理论依据:哮喘患者呼气中的挥发性有机化合物(VOCs)可能与痰中的嗜酸性粒细胞增多有关。我们开发了一种挥发性生物标志物来预测哮喘患者痰中的嗜酸性粒细胞增多:方法:将重症哮喘患者(36 人)痰液样本(顶空)上方空间释放的挥发性有机化合物收集到吸附管中,并使用热脱附气相色谱-质谱法(TD-GC-MS)进行分析。弹性净回归确定了与痰嗜酸性粒细胞≥3%相关的稳定挥发性有机化合物,并生成了挥发性生物标记特征。该挥发性有机化合物特征在以下人群的呼吸样本中得到了验证:(I) 英国 EMBER 联合会(n=65)和 U-BIOPRED-IMI 联合会(n=42)中根据血液嗜酸性粒细胞数≥0.3x109cells/L 或痰嗜酸性粒细胞数≥3% 的急性哮喘患者。呼吸样本被收集到吸附管(EMBER)或 Tedlar 袋(U-BIOPRED)中,并通过气相色谱-质谱法(GC×GC-MS -EMBER 或 GC-MS -U-BIOPRED)进行分析:主要结果:体外顶空气相鉴定出了 19 种与痰嗜酸性粒细胞增多症相关的挥发性有机化合物,得出的挥发性有机化合物特征对顶空气相中痰嗜酸性粒细胞增多症≥ 3% 的诊断准确率很高(AUROC (95% CI) 0.90(0.80-0.99), p结论:我们发现了痰嗜酸性粒细胞增多症的早期阶段,并为其提供了早期诊断方法:我们发现了与嗜酸性粒细胞气道炎症相关的挥发性生物标志物特征,并对其进行了早期临床验证。我们还需要做更多的工作,利用医疗点临床传感器来转化我们的发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Discovery and Validation of a Volatile Signature of Eosinophilic Airway Inflammation in Asthma.

Rationale: Volatile organic compounds (VOCs) in asthmatic breath may be associated with sputum eosinophilia. We developed a volatile biomarker signature to predict sputum eosinophilia in asthma. Methods: VOCs emitted into the space above sputum samples (headspace) from patients with severe asthma (n = 36) were collected onto sorbent tubes and analyzed using thermal desorption gas chromatography-mass spectrometry (GC-MS). Elastic net regression identified stable VOCs associated with sputum eosinophilia ⩾ 3% and generated a volatile biomarker signature. This VOC signature was validated in breath samples from: 1) patients with acute asthma according to blood eosinophilia ⩾0.3 × 109cells/L or sputum eosinophilia of ⩾3% in the UK EMBER (East Midlands Breathomics Pathology Node) consortium (n = 65) and 2) U-BIOPRED-IMI (Unbiased Biomarkers in Prediction of Respiratory Disease Outcomes Innovative Medicines Initiative) consortium (n = 42). Breath samples were collected onto sorbent tubes (EMBER) or Tedlar bags (U-BIOPRED) and analyzed by GC-MS (GC × GC-MS for EMBER or GC-MS for U-BIOPRED). Measurements and Main Results: The in vitro headspace identified 19 VOCs associated with sputum eosinophilia, and the derived VOC signature yielded good diagnostic accuracy for sputum eosinophilia ⩾3% in headspace (area under the receiver operating characteristic curve [AUROC] 0.90; 95% confidence interval [CI], 0.80-0.99; P < 0.0001), correlated inversely with sputum eosinophil percentage (rs = -0.71; P < 0.0001), and outperformed fractional exhaled nitric oxide (AUROC 0.61; 95% CI, 0.35-0.86). Analysis of exhaled breath in replication cohorts yielded a VOC signature AUROC (95% CI) for acute asthma exacerbations of 0.89 (0.76-1.0) (EMBER cohort) with sputum eosinophilia and 0.90 (0.75-1.0) in U-BIOPRED, again outperforming fractional exhaled nitric oxide in U-BIOPRED (0.62 [0.33-0.90]). Conclusions: We have discovered and provided early-stage clinical validation of a volatile biomarker signature associated with eosinophilic airway inflammation. Further work is needed to translate our discovery using point-of-care clinical sensors.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
27.30
自引率
4.50%
发文量
1313
审稿时长
3-6 weeks
期刊介绍: The American Journal of Respiratory and Critical Care Medicine focuses on human biology and disease, as well as animal studies that contribute to the understanding of pathophysiology and treatment of diseases that affect the respiratory system and critically ill patients. Papers that are solely or predominantly based in cell and molecular biology are published in the companion journal, the American Journal of Respiratory Cell and Molecular Biology. The Journal also seeks to publish clinical trials and outstanding review articles on areas of interest in several forms. The State-of-the-Art review is a treatise usually covering a broad field that brings bench research to the bedside. Shorter reviews are published as Critical Care Perspectives or Pulmonary Perspectives. These are generally focused on a more limited area and advance a concerted opinion about care for a specific process. Concise Clinical Reviews provide an evidence-based synthesis of the literature pertaining to topics of fundamental importance to the practice of pulmonary, critical care, and sleep medicine. Images providing advances or unusual contributions to the field are published as Images in Pulmonary, Critical Care, Sleep Medicine and the Sciences. A recent trend and future direction of the Journal has been to include debates of a topical nature on issues of importance in pulmonary and critical care medicine and to the membership of the American Thoracic Society. Other recent changes have included encompassing works from the field of critical care medicine and the extension of the editorial governing of journal policy to colleagues outside of the United States of America. The focus and direction of the Journal is to establish an international forum for state-of-the-art respiratory and critical care medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信